US Bioservices Dispensing Gilead’s EPCLUSA for All Genotypes of HCV

June 28, 2016

The U.S. Food and Drug Administration recently approved Gilead’s EPCLUSA (sofosbuvir 400 mg/velpatasvir 100 mg), the first oral single tablet regimen for the treatment of adults with genotypes 1-6 chronic hepatitis C virus (HCV) infection.